A Study of MEDI5395 in Combination with Durvalumab in Participants with Select Advanced Solid Tumors

Trial Identifier: D6450C00001
Sponsor: MedImmune, LLC
NCTID:: NCT03889275
Start Date: October 2019
Primary Completion Date: November 2021
Study Completion Date: December 2022
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Translation

Trial Locations

Country Location
ES Barcelona, ES, 8035
ES Madrid, ES, 28027
GB Guildford, GB, GU2 7WG
GB Leeds, GB, LS9 7TF
GB London, GB, SW3 6JJ
US, AZ Phoenix, AZ, US, 85054
US, CA La Jolla, CA, US, 92093
US, MN Rochester, MN, US, 55905
US, NC Chapel Hill, NC, US, 27599
US, NY Buffalo, NY, US, 14263
US, NY New York, NY, US, 10065
US, PA Pittsburgh, PA, US, 15232
US, RI Providence, RI, US, 02903